Article Details

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022

Retrieved on: 2022-03-08 04:02:48

Tags for this article:

Click the tags to see associated articles and topics

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022. View article details on HISWAI: https://www.bakersfield.com/ap/news/ikena-oncology-to-present-preclinical-findings-on-ik-930-a-novel-tead-inhibitor-at-the/article_47da9feb-6563-5c5b-bb0f-c4c893b29457.html

Excerpt

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in ...

Article found on: www.bakersfield.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up